Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group

5Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Quality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaboration span the sharing of knowledge and ideas, the sharing of analytics methods, discussion of talent upskilling and technology adoption strategies, and collaborative discussion on these potential changes with global Health Authorities.

Cite

CITATION STYLE

APA

Ménard, T., Young, K., Siegel, L., Emerson, J., Studt, R., Sidor, L., … Ring, S. (2021). Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group. CPT: Pharmacometrics and Systems Pharmacology, 10(8), 799–803. https://doi.org/10.1002/psp4.12677

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free